IPSC compared with ACRS: revenue, margins and what each company keeps, and the suppliers and customers both name

IPSCCentury Therapeutics, Inc.

Mkt capRevenueRevenue

ACRSAclaris Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

IPSCCentury Therapeutics, Inc.

ACRSAclaris Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

IPSC1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±29.8%▼−4.85%×0.16

ACRS

0 of 4at or beyond implied

Reportimpliedrealized× implied

Oct 27 '26±33.1%0.00%×0.00

Q2 FY26±18.4%▼−4.25%×0.23

= impliedIPSC realized, solidACRS realized, hatchedOne scale, both sides: full bar = 34%× = |realized| ÷ impliedSource: market data

May 7 '26

±11.5%

▲+1.67%

×0.15

Q1 FY26±16.7%▼−5.44%×0.32

IPSCCentury Therapeutics, Inc.

1.49▲+1.76%· post 1.48

Mkt cap$266.2MRevenue$109MQ1 FY25Revenue$7MFY24

ACRSAclaris Therapeutics, Inc.

3.98▼−0.35%· post 3.98

ClosedOct 30 '26

Mkt cap$584.4MRevenue$2MQ2 FY26Revenue$8MFY25

Compare

ClosedOct 30 '26

IPSCCentury Therapeutics, Inc.

ACRSAclaris Therapeutics, Inc.

1.49▲+1.76%post 1.48

Price

3.98▼−0.35%post 3.98

$266.2M

Mkt cap

$584.4M

Q1 FY25$109M

Revenue

$2MQ2 FY26

FY24$7M

Revenue

$8MFY25

IPSC1.49▲+1.76%vsACRS3.98▼−0.35%ClosedOct 30 '26